Novartis confirms benefits of first-line Tasigna treatment seen in earlier trials in newly-diagnosed patients with chronic myeloid leukemia (CML)

Patients on Tasigna achieved rapid and high rates of molecular response with a very low rate of progression to advanced disease ENEST1st data confirm the favorable benefit/risk profile of Tasigna in newly-diagnosed CML patients seen in the pivotal ENESTnd study … Read the full press release →